ACADIA Pharmaceuticals Announces Election of Stephen R. Biggar to Its Board of Directors

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders,today
announced the election of Stephen R. Biggar, M.D., Ph.D., to its board
of directors. Dr. Biggar will fill a vacancy on ACADIA’s board and serve
as a Class II director. The terms of the Class II directors will expire
at the annual meeting of stockholders in 2015.

“This is a particularly exciting time to join the ACADIA board following
the highly successful results from the pivotal Phase III Parkinson’s
disease psychosis trial with pimavanserin,” said Dr. Biggar. “I share in
ACADIA’s enthusiasm and belief that pimavanserin has the potential to
transform the treatment landscape for patients suffering from this
serious disorder and may also offer an improved therapy option for a
broader range of neuropsychiatric disorders. Following the recent
financing, which raised $86 million, ACADIA has a solid foundation for
building the full potential of pimavanserin. I look forward to being a
part of the ACADIA team as we work to develop and commercialize
pimavanserin and other potential new drugs that may improve the lives of
patients.”

Dr. Biggar serves as a Partner at Baker Brothers Investments, a fund
management company focused on long-term investments in life-sciences
companies. From April 2002 to October 2006, he served as a Principal
with Baker Brothers Investments which he had joined as an Associate in
April 2000. Prior to joining Baker Brothers, Dr. Biggar received an M.D.
and a Ph.D. in Immunology from Stanford University and received a B.S.
in Genetics from the University of Rochester. Dr. Biggar also serves as
a director for Synageva BioPharma Corp., a publicly traded biotechnology
company.

“We are delighted that Steve has joined ACADIA’s board,” said Uli
Hacksell, Ph.D., ACADIA’s Chief Executive Officer. “His extensive
experience as an investor in a wide range of biotechnology companies
together with his medical and scientific training will provide our board
with a unique perspective and enhance our collective experience.”

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatments
that address unmet medical needs in neurological and related central
nervous system disorders. ACADIA has a pipeline of product candidates
led by pimavanserin, which is in Phase III development as a potential
first-in-class treatment for Parkinson's disease psychosis. ACADIA also
has clinical-stage programs for chronic pain and glaucoma in
collaboration with Allergan, Inc. and two advanced preclinical programs
directed at Parkinson’s disease and other neurological disorders. All
product candidates are small molecules that emanate from discoveries
made at ACADIA. ACADIA maintains a website at www.acadia-pharm.com
to which ACADIA regularly posts copies of its press releases as well as
additional information and through which interested parties can
subscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the progress and timing of ACADIA’s
drug discovery and development programs, either alone or with a partner,
and the clinical benefits to be derived from ACADIA’s product
candidates, in each case including pimavanserin. In particular,
forward-looking statements include statements regarding the impact of
ACADIA’s recent financing and the potential for pimavanserin to
transform the treatment landscape for Parkinson’s disease psychosis and
to be an improved therapy for a broader range of neuropsychiatric
disorders. These statements are only predictions based on current
information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from those
projected in any of such statements due to various factors, including
the risks and uncertainties inherent in drug discovery, development and
commercialization, and collaborations with others, and the fact that
past results of clinical trials may not be indicative of future trial
results. For a discussion of these and other factors, please refer to
ACADIA’s annual report on Form 10-K for the year ended December 31, 2011
as well as ACADIA’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. This
caution is made under the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. All forward-looking statements
are qualified in their entirety by this cautionary statement and ACADIA
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as
required by law.